LaGrange

Lagrange Therapeutics is an early-stage biotechnology company focused on harnessing the non-canonical functions of aminoacyl-tRNA synthetases to develop novel therapeutics. Founded by renowned scientist Paul Schimmel and Xiang-Lei Yang, the company leverages decades of research into the expanded biological roles of these ancient enzymes beyond their traditional function in protein synthesis. Lagrange's platform identifies specific tRNA synthetase-derived fragments and variants that act as extracellular signaling molecules to modulate immune responses and tissue homeostasis. The company's pipeline is primarily directed toward addressing unmet needs in autoimmune conditions, chronic inflammation, and oncology. By targeting these fundamental regulatory pathways, Lagrange Therapeutics aims to create a new class of precision biologics with broad therapeutic potential.